Cost-effectiveness of defibrotide for treatment of severe veno-occlusive disease: it is time for evidence based economic evaluations
Open Access
- 1 January 2021
- journal article
- editorial
- Published by Taylor & Francis Ltd in Journal of Medical Economics
- Vol. 24 (1), 727-729
- https://doi.org/10.1080/13696998.2021.1929259
Abstract
Rodriguez et al present in this issue a cost-effectiveness analysis of Defibrotide (DefitelioR) for the treatment of severe veno-occlusive disease in the context of hematopoietic stem cell transpla...This publication has 17 references indexed in Scilit:
- Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Assessment, Diagnosis, and Management by the GITMO GroupTransplantation, 2021
- Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in SpainJournal of Medical Economics, 2021
- FDA Approval and Regulation of Pharmaceuticals, 1983-2018JAMA, 2020
- Efficacy and Safety of Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-AnalysisSeminars in Thrombosis and Hemostasis, 2019
- Hepatic ComplicationsPublished by Springer Science and Business Media LLC ,2018
- A systematic review of pharmacoeconomic guidelinesJournal of Medical Economics, 2017
- Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failureBlood, 2016
- Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trialThe Lancet, 2012
- Veno‐occlusive disease of the liver after hemopoietic cell transplantationEuropean Journal of Haematology, 2000
- PGI2-generation and antithrombotic activity of orally administered defibrotidePharmacological Research Communications, 1982